Growth hormone is released from the pituitary gland in natural pulses throughout the day, orchestrating processes from tissue maintenance to metabolic regulation. Rather than introducing synthetic growth hormone directly, a class of research peptides works by signaling the body's own pituitary to release GH through its native pathways. Several peptides have become central to this area of investigation, each engaging the pituitary through a distinct route: Ipamorelin, Sermorelin, CJC-1295, and Tesamorelin.
Ipamorelin
What it is: A selective five-amino-acid growth hormone secretagogue that triggers natural GH release from the pituitary gland without significantly affecting cortisol or prolactin levels.
How It Works
What Researchers Study It For
Common Research Protocols
In published research, Ipamorelin is supplied as a lyophilized powder and reconstituted with bacteriostatic water. It is typically administered via subcutaneous injection.
Community Interest Areas
Ipamorelin has generated significant research interest due to its selectivity profile. Unlike earlier secretagogues, it does not appear to significantly elevate cortisol, ACTH, or prolactin in research settings. This makes it a preferred compound in studies investigating isolated GH signaling without confounding hormonal variables. It is frequently paired with CJC-1295 in combined protocols.
Sermorelin
What it is: A synthetic analog of growth hormone-releasing hormone (GHRH) made up of its first 29 amino acids — GHRH(1-29), the shortest fragment that retains the full biological activity of GHRH.
How It Works
What Researchers Study It For
Common Research Protocols
Sermorelin is supplied as a lyophilized powder, reconstituted with bacteriostatic water, and typically administered via subcutaneous injection. Research has characterized its ability to elicit dose-dependent GH release from the anterior pituitary; although the peptide is cleared rapidly, GH levels have been reported to remain elevated for roughly three hours after administration. Source
Community Interest Areas
Sermorelin draws research interest as the minimal GHRH fragment that retains full activity, making it a common reference compound for studying the GHRH-receptor pathway. Because it prompts the pituitary to release its own GH rather than supplying it exogenously, investigators study it in contexts where preserving the body's natural feedback regulation is a priority.
CJC-1295
What it is: A long-acting GHRH analog based on a modified GHRH(1-29) sequence. In its DAC (Drug Affinity Complex) form, CJC-1295 binds to circulating serum albumin after administration, which protects it from rapid breakdown and extends its half-life from minutes to several days. It is most often studied alongside Ipamorelin.
How It Works
The CJC-1295 + Ipamorelin pairing is one of the most widely studied secretagogue combinations: CJC-1295 acts through the GHRH receptor while Ipamorelin acts through the ghrelin receptor, so the two engage complementary pathways rather than the same one.
What Researchers Study It For
Common Research Protocols
CJC-1295 is reconstituted from lyophilized powder and administered via subcutaneous injection. In healthy adults, a single dose has been reported to increase mean GH levels by roughly 46% and IGF-1 by roughly 45%, with effects sustained for several days. Source Research has also shown that GH secretion remains pulsatile even under the peptide's continuous stimulation. Source
Community Interest Areas
CJC-1295 is of particular interest for its extended duration of action, which allows less frequent administration than native GHRH. The CJC-1295 + Ipamorelin combination remains one of the most widely studied secretagogue pairings, because the two compounds act on complementary pathways — GHRH-receptor and ghrelin-receptor — in research on additive GH release.
Learn More About CJC-1295 / Ipamorelin
Tesamorelin
What it is: A synthetic analog of growth hormone-releasing hormone (GHRH) consisting of the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid modification that improves stability.
How It Works
What Researchers Study It For
Common Research Protocols
Tesamorelin is reconstituted from lyophilized powder and administered via subcutaneous injection. It is one of the few GH-releasing peptides that has undergone extensive clinical evaluation, including large-scale trials examining its effects on trunk fat in the context of HIV-associated lipodystrophy. Research protocols typically involve daily administration over multi-week study periods. Source
Community Interest Areas
Tesamorelin draws substantial research interest in metabolic and body composition studies, particularly in models investigating visceral fat accumulation. Because it works through the GHRH receptor rather than the ghrelin pathway, it is often explored alongside ghrelin-mimetic peptides like Ipamorelin in dual-pathway research protocols designed to study synergistic GH release.
How They Compare
Key Takeaways
- Ipamorelin is studied for its selective activation of the ghrelin receptor pathway, triggering endogenous GH pulses without significantly elevating cortisol or prolactin
- Sermorelin is the minimal GHRH(1-29) fragment that retains full activity, studied as a reference compound for GHRH-receptor signaling and endogenous, pulsatile GH release
- CJC-1295 is a long-acting GHRH analog that binds serum albumin to extend its half-life to days, and is most often studied paired with Ipamorelin for complementary-pathway GH release
- Tesamorelin works through the GHRH receptor to stimulate both the production and release of growth hormone, with extensive clinical-stage research in metabolic contexts
- Ipamorelin acts through the ghrelin receptor while Sermorelin, CJC-1295, and Tesamorelin act through the GHRH receptor — which is why researchers frequently study them together in dual-mechanism protocols
- All four compounds promote endogenous GH release rather than introducing exogenous growth hormone, preserving the body's natural pulsatile secretion pattern and feedback regulation
- The statements made on this website have not been evaluated by the U.S. Food and Drug Administration (FDA). All products sold by 33 Degrees of Healing are provided strictly for research, laboratory, and investigational purposes only.
Related Research Compounds
Sources
- Raun K, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998. PubMed
- Prakash A, Goa KL. Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency. BioDrugs. 1999. PubMed
- Walker RF. Sermorelin: a better approach to management of adult-onset growth hormone insufficiency? Clin Interv Aging. 2006. PMC
- Teichman SL, et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295, a long-acting GHRH analog, in healthy adults. J Clin Endocrinol Metab. 2006. PubMed
- Ionescu M, Frohman LA. Pulsatile secretion of GH persists during continuous stimulation by CJC-1295, a long-acting GHRH analog. J Clin Endocrinol Metab. 2006. PubMed
- Falutz J, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007. PubMed
- Stanley TL, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. JAMA. 2014. PubMed
This article is for educational and research purposes only. It is not intended as medical advice. The compounds discussed are research chemicals not approved by the FDA for human use. Always consult qualified professionals and review current regulations before conducting any research.